相关实验视频

Updated: Sep 19, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

针对WEE1,以克服EGFR突变肺癌中的ARID1A突变驱动的奥西默提尼布抗性

Koji Fukuda¹, Shigeki Nanjo², Shinji Takeuchi³

¹Division of Innovative Cancer Control Research, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

|June 15, 2025

概括

富含AT相互作用域含有蛋白1A (ARID1A) 突变驱动EGFR突变NSCLC中的奥西默提尼布耐药性. 抑制WEE1激酶为ARID1A突变患者提供了一个有前途的治疗策略,改善了结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

奥西默提尼布是EGFR突变NSCLC的第一线EGFR氨酸激酶抑制剂 (EGFR-TKI).
对奥西默蒂尼布的耐药性是一个重要的临床挑战,其机制尚未完全理解.
识别耐药性驱动因素和治疗策略对于改善患者的治疗结果至关重要.

研究的目的:

调查EGFR突变NSCLC中奥西默提尼布耐药性背后的机制.
确定潜在的治疗点,以克服 osimertinib 的耐药性.
为了评估ARID1A突变在受 osimertinib 治疗的患者中的临床意义.

主要方法:

在一只小鼠模型中诱导了奥西默蒂尼布耐药性.
使用下一代测序和CRISPR-Cas9淘汰屏幕来识别耐药性突变和治疗点.
分析了临床样本,以将ARID1A状态与患者生存结果相关联.

主要成果:

在AT丰富的相互作用域含有蛋白1A (ARID1A) 基因中的突变被确定为奥西默提尼布耐药性的主要机制.
通过改变细胞循环调节和DNA修复途径,ARID1A突变赋予了耐药性.
在临床前模型中和与EGFR抑制相结合,WEE1激酶抑制在克服ARID1A突变 osimertinib耐药性方面表现出有效性.
从临床角度来看,ARID1A突变与用osimertinib治疗的患者的无进展和整体存活时间显著缩短有关.

结论:

在NSCLC中,ARID1A突变作为预测奥西默提尼布耐药性的关键生物标志物.
向WEE1激酶代表了ARID1A突变异型 osimertinib耐药NSCLC的一个有前途的治疗策略.
对EGFR和WEE1的联合抑制需要对这一患者群体进行进一步的临床研究.

关键词:

在ARID1A突变中.药物耐药性药物耐药性药物耐药性勒普托门内尔癌症 (Leptomeningeal carcinomatosis) 是一种癌症的发生.奥西默蒂尼布 (Osimertinib) 是一种药物.在WEE1激酶中,

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...